Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer

Oncogene

Volumn 27, Issue 56, 2008, Pages 7094-7105

  Wolf, I ^a,b   Levanon Cohen, S ^a,c   Bose, S ^d   Ligumsky, H ^a   Sredni, B ^c   Kanety, H ^a   Kuro O, M ^e   Karlan, B ^f   Kaufman, B ^a   Koeffler, H P ^d   Rubinek, T ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f Women's Cancer Research Institute   (United States)

Author keywords

Breast cancer; Insulin; Insulin growth factor 1; Klotho; Tumor suppressor

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; FIBROBLAST GROWTH FACTOR; KI 67 ANTIGEN; KLOTHO PROTEIN; PROTEIN P53; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR VOLUME; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLUCURONIDASE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; KI-67 ANTIGEN; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES; TISSUE ARRAY ANALYSIS;

MUS;

EID: 58149229326     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.292     Document Type: Article

References (41)

1. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF et al. (2003). KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 72: 1154-1161.
2. Arking DE, Krebsova A, Macek Sr M, Macek Jr M, Arking A, Mian IS et al. (2002). Association of human aging with a functional variantof klotho. Proc Natl Acad Sci 99: 856-861.
3. Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E. (2001). Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 61: 6747-6754.
4. Cha S-K, Ortega B, Kurosu H, Rosenblatt KP, Kuro-o M, Huang C-L. (2008). Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci 105: 9805-9810.
5. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. (2005). The {beta}-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310: 490-493.
6. Chen C-D, Podvin S, Gillespie E, Leeman SE, Abraham CR. (2007). Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci 104: 19796-19801.
7. Chihara Y, Rakugi H, Ishikawa K, Ikushima M, Maekawa Y, Ohta J et al. (2006). Klotho protein promotes adipocyte differentiation. Endocrinology 147: 3835-3842.
8. de Oliveira RM. (2006). Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Letters 580: 5753-5758.
9. den Dekker E, Hoenderop JGJ, Nilius B, Bindels RJM. (2003). The epithelial calcium channels, TRPV5 & TRPV6: from identification towards regulation. Cell Calcium 33: 497-507.
10. Fenig E, Szyper-Kravitz M, Yerushalmi R, Lahav M, Beery E, Wasserman L et al. (2002). Basic fibroblast growth factor mediated growth inhibition in breast cancer cells is independent of ras signaling pathway. Oncol Rep 9: 875-877.
11. Fenig E, Wieder R, Paglin S, Wang H, Persaud R, Haimovitz-Friedman A et al. (1997). Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells. Clin Cancer Res 3: 135-142.
12. Geier A, Beery R, Haimsohn M, Karasik A. (1995). Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance. Cancer Invest 13: 480-486.
13. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. (2005). Down-regulation and growth inhibitory role of C/EBP{alpha} in breast cancer. Clin Cancer Res 11: 3184-3190.
14. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J. (2006). C/EBP[beta] at the core of the TGF[beta] cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10: 203-214.
15. Haimsohn M, Beery R, Karasik A, Kanety H, Geier A. (2002). Aurintricarboxylic acid induces a distinct activation of the IGF-I receptor signaling within MDA-231 cells. Endocrinology 143: 837-845.
16. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG et al. (2006). In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66: 362-371.
17. Hsiung R, Zhu W, Klein G, Qin W, Rosenberg A, Park P et al. (2002). High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer J 8: 303-310.
18. Ikushima M, Rakugi H, Ishikawa K, Maekawa Y, Yamamoto K, Ohta J et al. (2006). Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 339: 827-832.
19. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N et al. (2004). Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565: 143-147.
20. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A et al. (2007). {alpha}-klotho as a regulator of calcium homeostasis. Science 316: 1615-1618.
21. Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T et al. (2000). Molecular cloning and expression analyses of mouse [beta]klotho, which encodes a novel Klotho family protein. Mech Dev 98: 115-119.
22. Kato Y, Arakawa E, Kinoshita S, Shirai A, Furuya A, Yamano K et al. (2000). Establishment of the anti-klotho monoclonal antibodies and detection of klotho protein in kidneys. Biochem Biophys Res Commun 267: 597-602.
23. Kim Y, Kim J-H, Nam YJ, Kong M, Kim YJ, Yu K-H et al. (2006). Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. Neurosci Lett 407: 189-194.
24. Korah RM, Sysounthone V, Golowa Y, Wieder R. (2000). Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. Cancer Res 60: 733-740.
25. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. (1997). Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51.
26. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP et al. (2006). Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 281: 6120-6123.
27. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al. (2005). Suppression of aging in mice by the hormone Klotho. Science 309: 1829-1833.
28. Lacroix M, Leclercq G. (2004). Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treatment 83: 249-289.
29. Li X, Kim JW, Gronborg M, Urlaub H, Lane MD, Tang Q-Q. (2007). Role of cdk2 in the sequential phosphorylation/activation of C/EBPbeta during adipocyte differentiation. Proc Natl Acad Sci 104: 11597-11602.
30. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y. (1998). Identification of the human Klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun 242: 626-630.
31. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. (2004). Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230.
32. Ohyama Y, Kurabayashi M, Masuda H, Nakamura T, Aihara Y, Kaname T et al. (1998). Molecular cloning of rat klotho cDNA: markedly decreased expression of klotho by acute inflammatory stress. Biochem Biophys Res Commun 251: 920-925.
33. Shiraki-Iida T, Aizawa H, Matsumura Y, Sekine S, Iida A, Anazawa H et al. (1998). Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett 424: 6-10.
34. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K et al. (2006). Klotho converts canonical FGF receptor into a specific receptor for FGF23. Science 444: 770-774.
35. Utsugi T, Ohno T, Ohyama Y, Uchiyama T, Saito Y, Matsumura Y et al. (2000). Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism 49: 1118-1123.
36. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J, Hondermarck H. (2005). The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-[kappa]B activation induced via interaction between Akt and I[kappa]B kinase-[beta] in breast cancer cells. Oncogene 24: 5482-5491.
37. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. (2007). FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 120: 1013-1022.
38. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT et al. (2006a). 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66: 7818-7823.
39. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ et al. (2006b). Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 42: 1077-1082.
40. Yee D. (2006). Targeting insulin-like growth factor pathways. Br J Cancer 94: 465-468.
41. Zarrabeitia M, Hernández JL, Valero C, Zarrabeitia A, Ortiz F, Gonzalez-Macias J et al. (2007). Klotho gene polymorphism and male bone mass. Calcif Tissue Int 80: 10-14.